Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts

L C Gilbert1, H Chen, X Lu

  • 1VA Medical Center, Decatur, GA 30033, USA. Linda.Gilbert3@va.gov

Bone
|June 13, 2013
PubMed

Insights

Low-dose tumor necrosis factor-alpha (TNF-α) suppresses osteoblast activity and bone accrual in young mice. This early effect on bone formation occurs independently of osteoclast activity and involves TNF-α inhibition of the Wnt pathway.

Area of Science:

  • Bone Biology
  • Inflammation
  • Skeletal Development

Background:

  • Tumor necrosis factor-alpha (TNF-α) is implicated in bone loss in arthritis and aging.
  • Its effects on the young, growing skeleton are less understood.
  • Investigating TNF-α's role in early skeletal development is crucial.

Purpose of the Study:

  • To elucidate the mechanism by which TNF-α affects bone accrual in young mice.
  • To determine if TNF-α impacts osteoblasts, osteoclasts, or both in the developing skeleton.
  • To identify the molecular pathways involved in TNF-α-mediated effects on bone formation.

Main Methods:

  • Utilized TNF transgenic (TgTNF) mice expressing low levels of human TNF-α.
  • Performed bone histomorphometry and assessed osteoblast and osteoclast markers.
  • Analyzed Wnt signaling pathway components and Wnt reporter gene activity.
  • Compared TgTNF mice with wild-type (WT) littermates at various ages.

Main Results:

  • TgTNF mice showed suppressed osteoblast numbers and delayed bone accrual during a critical early period (up to 6 weeks).
  • No significant differences were observed in osteoclast number, activity, or resorption markers between TgTNF and WT mice.
  • Reduced canonical Wnt signaling and Wnt-regulated gene expression were detected in TgTNF mice, linked to impaired β-catenin nuclear translocation.
  • Wnt reporter activity was diminished in TgTNF mice, confirming suppressed Wnt pathway activation.

Conclusions:

  • Low-dose TNF-α is sufficient to inhibit the critical early surge in osteoblast activity and bone formation in young mice.
  • This inhibition occurs independently of effects on osteoclasts and bone resorption.
  • TNF-α suppresses osteoblastogenesis, at least in part, by interfering with the Wnt signaling pathway during early skeletal development.

Related Concept Videos

Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...